Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension

Journal of Hypertension

Volumn 17, Issue 2, 1999, Pages 293-302

  Karlberg, Bengt E ^a   Lins, Lars Eric ^b   Hermansson, Karin ^b  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b Boehringer Ingelheim AB   (Sweden)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin converting enzyme inhibitor; AT1 receptor antagonist; Elderly; Enalapril; Hypertension; Telmisartan

Indexed keywords

ANTIHYPERTENSIVE AGENT; ENALAPRIL; HYDROCHLOROTHIAZIDE; TELMISARTAN;

ABDOMINAL PAIN; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FLATULENCE; GASTRITIS; HEADACHE; HUMAN; HYPERTENSION; HYPERURICEMIA; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUPINE POSITION; SWEATING; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; UPPER RESPIRATORY TRACT INFECTION; VERTIGO;

EID: 0032970904     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917020-00015     Document Type: Article

References (31)

1. Laragh JH, Baer L, Brunner HR, Bühler, FR, Sealey JE, Vaughan ED. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52:633-652.
2. Urata H, Boehm KD, Philip AK, Kinoshita A, Gabrovsek J, Bumpus FM, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest 1993; 91:1269-1281.
3. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30:55-61.
4. Semple PF. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J Hypertens 1995; 13 (Suppl 3);S17-S21.
5. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfieid P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45;205-251.
6. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enatapril in patients with essential hypertension. J Hypertens 1995; 13;1343-1351.
7. Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14:1147-1151.
8. Chan P, Tomlinson B, Huang TY, Ko JT, Lin TS, Lee YS. Double-blind comparison of losartan, tisinopril, and metolazone in elderly patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol 1997; 37:253-257.
9. Benz J, Oshrain C, Henry D, Avery C, Chiang YT, Gatlin M, Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37:101-107.
10. Ries UJ, Mihm G, Narr B, Hasselbach KM, Wittneban H, Entzeroth M, et al. 6-Substituted benzimidazoles as new nonpeptide angiotensin II receptor antagonists: synthesis, biological activity, and structure-activity relationships. J Med Chem 1993; 36:4040-4051.
11. Wienen W, Hauel N, Van Meel JCA, Narr B, Ries U, Entzeroth M. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277. Br J Pharmacol 1993; 110:245-252.
12. Bohm M, Lee M, Kreutz R, Kim S, Schinke M, Djavidani B, et al. Angiotensin II receptor blockade in TGR(mREN2)27: effects of renin-angiotensin-system gene expression and cardiovascular functions. J Hypertens 1995; 13:897-899.
13. 1 selective angiotensin II antagonist, telmisartan, on hemodynamics and ventricular function after cardiopulmonary resuscitation in pigs, Resuscitation 1997; 35:61-68.
14. van Meel JC, Redemann N, Haigh RM. Hypotensive effects of the angiotensin II antagonist telmisartan in conscious chronically-instrumented transgenic rats. Arzneimittelforschung 1996; 46:755-759.
15. Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M. Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163, 164:217-221.
16. Smith DHG, Neutel JM, Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15:229-240.
17. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15:206-217.
18. Burrell LM, Johnston Cl. Angiotensin II receptor antagonists: potential in elderly patients with cardiovascular disease. Drugs Aging 1997; 10:421 -434.
19. Ware JE, Sherbourne CD. The MOS 36-Item short-form health survey. Med Care 1992; 30:473-483.
20. Fyhrqvist F, Soveri P, Puutula L, Stenman U. Radio-immunoassay of plasma renin activity. Clin Chem 1976; 22:250-256.
21. Nyström F, Karlberg BE, Öhman KP. Serum angiotensin-converting enzyme activity correlates positively with plasma angiotensin II: a population-based study of ambulatoty blood pressure and the renin-angiotensin system. J Hum Hypertens 1997; 11:301-306.
22. Karlberg BE, Tolagen K. Age, blood pressure, renin and urinary electrolytes in primary hypertension and in the normotensive state. Scand J Clin Invest 1978; 38:319-327.
23. Dahlof B, Hansson L, Acosta JH, Bolzano K, Fairhurst G, Ferreira C, et al. Controlled trial of enalapril and hydrochlorothiazíde in 200 hypertensive patients. Am J Hypertens 1988; 1:38-41.
24. Ruilope LM, Simpson RL, Toh J, Arcuri KE, Goldberg AI, Sweet CS. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood Press 1996; 5:32-40.
25. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al. A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1999 (in press).
26. Mallion JM, Lacourcière Y. A comparison of the blood pressure profile of telmisartan and losartan at 18-24 hours post-dosing as measured by ambulatory blood pressure monitoring (ABPM) [abstract E141]. Am J Hypertens 1998; 11;262A.
27. Townsend R, Haggert B, Liss C, Edelman JM. Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension. Clin Ther 1995; 17:911-923.
28. Hämmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998; 35:49-64.
29. Weisser K, Schloos J, Jakob S, Muhlberg W, Platt D, Mutschler E. The influence of hydrochlorothiazide on the pharmacokinetics of enalapril in elderly patients. Eur J Clin Pharmacol 1992; 43:173-177.
30. Leas KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther 1987; 41:597-602.
31. Piepho RW, Fendler KJ. Antihypertensive therapy in the aged patient: clinical pharmacokinetic considerations. Drugs Aging 1991; 1:194-211.